NCT00094757View on ClinicalTrials.gov

An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023)

PHASE3CompletedINTERVENTIONAL
Enrollment

521

Participants

Timeline

Start Date

October 6, 2004

Primary Completion Date

August 17, 2005

Study Completion Date

April 28, 2006

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Comparator: sitagliptin 100 mg

sitagliptin 100 mg oral tablet once daily for 54 weeks

DRUG

Comparator: sitagliptin 200 mg

sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks

DRUG

Comparator: placebo

placebo oral tablet once daily during Phase A (Weeks 0-18)

DRUG

Comparator: pioglitazone

pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00094757 - An Investigational Drug Study in Patients With Type 2 Diabetes Mellitus (MK0431-023) | Biotech Hunter | Biotech Hunter